Industry committee  Sometimes—often—the whole of the Canadian market for these products can be much less than $1 million in all provinces, all jurisdictions. Just your regulatory fee is $170,000, and you also have to pay a fee for the Canadian Agency for Drugs and Technologies in Health, CADTH, to

Industry committee  In fact, U.S. comparison can be detrimental to Canada because the fees are roughly the same in the U.S. and in Canada except that the market is 10 times smaller here. The cost of getting the drug to market, with this fee structure, is disproportionate in Canada.

Industry committee  I think the answer to this is that, from the start, the patient populations are very small in pediatrics. Also, these are disease states that are almost regularly rare diseases. The formulation problems happen with drugs that have been on the market for many years, have become ge

Industry committee  If I may add, Mr. Chairman, I think that the pediatric example is a perfect one of a regulatory problem that has become chronic. I'm a pharmacist by training, and I was trained as a hospital pharmacist at the Sainte-Justine hospital in the 1970s. Already the problem was in existe